Omalizumab Dosing and Administration
For chronic spontaneous urticaria (CSU), start omalizumab at 300 mg subcutaneously every 4 weeks, and for insufficient response, escalate to a maximum of 600 mg every 2 weeks. 1
Chronic Spontaneous Urticaria (CSU)
Standard Dosing
- Initial dose: 300 mg subcutaneously every 4 weeks 1, 2
- Dosing is NOT dependent on serum IgE levels or body weight 2
- Can be administered as one 300 mg/2 mL injection or two 150 mg/mL injections 2
Dose Escalation Strategy
If inadequate response after standard dosing:
- Escalate by shortening interval and/or increasing dose 1
- Maximum recommended dose: 600 mg every 2 weeks 1
- Allow up to 6 months for patients to respond before considering treatment failure 1
The 2022 international urticaria guidelines emphasize that updosing is particularly beneficial in patients with high body mass index 1. The safety profile of higher doses mirrors that of standard dosing, with the risk-benefit profile superior to cyclosporine (the third-line alternative) 1.
Response Timeline
- Some patients respond before week 4 3
- Median time to well-controlled urticaria (UAS7 ≤6): 6 weeks 3
- Median time to complete response (UAS7=0): 12-13 weeks 3
- Response is dose-dependent, with 300 mg showing superior efficacy compared to 150 mg or 75 mg 3
Allergic Asthma
Dosing Determination
Dose is based on BOTH pre-treatment serum total IgE level (IU/mL) AND body weight (kg) 2
Adults and Adolescents ≥12 years:
- Range: 75-375 mg subcutaneously every 2 or 4 weeks 2
- Refer to FDA dosing table based on IgE (30-700 IU/mL) and weight (30-150 kg) 2
Pediatric Patients 6 to <12 years:
Important Caveats
- Total IgE levels remain elevated during treatment and up to 1 year after discontinuation 2
- Do NOT retest IgE during treatment for dose adjustment 2
- For treatment interruptions <1 year: use original IgE levels 2
- For interruptions ≥1 year: retest IgE for new dose determination 2
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Dose: 75-600 mg subcutaneously every 2 or 4 weeks based on pre-treatment serum total IgE level and body weight 2
- Use adult dosing table for CRSwNP 2
- Approved for adults only
IgE-Mediated Food Allergy
Dose: 75-600 mg subcutaneously every 2 or 4 weeks based on pre-treatment serum total IgE level and body weight 2
Administration Guidelines
Route and Setting
- Subcutaneous injection only 2
- Must initiate therapy in a healthcare setting due to anaphylaxis risk 2
Self-Administration Eligibility
After establishing safety, patients may self-administer if they meet ALL criteria:
- No prior anaphylaxis to omalizumab (for asthma/CRSwNP/CSU) or other agents except foods (for food allergy) 2
- Received ≥3 doses under healthcare supervision without hypersensitivity reactions 2
- Can recognize and treat anaphylaxis appropriately 2
- Can perform subcutaneous injections correctly 2
Device Options
- Prefilled syringe: Available for ages ≥1 year (requires caregiver administration for ages 1-11) 2
- Autoinjector: Only for ages ≥12 years 2
Key Clinical Pearls
CSU-Specific Considerations
- Positive basophil histamine release assay (BHRA) predicts need for dose escalation (HR: 2.79) 4
- Fast treatment response and higher baseline UCT scores decrease escalation risk 4
- Male sex and fast response predict successful dose reduction 4
- Longer pre-treatment symptom duration (>7.5 months) increases relapse risk after discontinuation 5
Duration of Therapy
- CSU: Appropriate duration not established; periodically reassess need 2
- Asthma/CRSwNP: Periodically reassess based on disease severity and control 2
- Food allergy: Duration not evaluated; periodically reassess 2
Common Pitfall
The most critical error is using weight/IgE-based dosing for CSU—this only applies to asthma, CRSwNP, and food allergy 2. For CSU, always use fixed dosing (150 or 300 mg every 4 weeks), with the 300 mg dose strongly preferred as initial therapy based on superior efficacy data 1, 3.